New peptide serum takes on hair loss in head-to-head trial
NCT ID NCT07536100
First seen Apr 23, 2026 · Last updated Jun 14, 2026 · Updated 6 times
Summary
This study compares a new peptide-based hair serum to the standard treatment minoxidil for people with pattern baldness. About 80 adults with mild to moderate hair loss will use one of the two treatments for 24 weeks. Researchers will measure changes in hair density and thickness to see if the peptide serum works as well or better than minoxidil.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA (AGA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Institute of Dermatology
RECRUITINGBangkok, Thailand
-
Institute of dermatology
RECRUITINGBangkok, Bangkok, 10400, Thailand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.